JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Biocryst Pharmaceuticals on Tuesday, setting a price target of $23, which is approximately 59.06% above the present share price of $14.46.
Wolleben expects Biocryst Pharmaceuticals to post earnings per share (EPS) of -$0.24 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in BioCryst (NASDAQ:BCRX), with an average price target of $21.67.
The analysts price targets range from a high of $30 to a low of $16.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $49.96 million and a net profit of -$29.58 million. The company's market cap is $2.59 billion.
According to TipRanks.com, JMP Securities analyst Jonathan Wolleben is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 10.3% and a 42.31% success rate.
BioCryst Pharmaceuticals , Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.